Evidence map›Paper›PMID 41534718›Full record

ArticleThe Journal of allergy and clinical immunology2026

Alpha-gal-specific human IgE promotes both alpha-gal-induced and antigen-independent allergic effector cell activation.

Yinghui Wang, Yugen Zhang, Christa Dudley, Katherine Fitzgerald, Audrey S Carson, Camille M Kapita, Daaniya Rana, Kim Kluckman, Donna Bortner, Dale O Cowley and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yinghui WangDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Allergy Mast Cell Disorders Program, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Yugen ZhangDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Christa DudleyDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Katherine FitzgeraldDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Audrey S CarsonDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Camille M KapitaDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Daaniya RanaDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Kim KluckmanUNC Animal Models Core, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Donna BortnerUNC Animal Models Core, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Dale O CowleyUNC Animal Models Core, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Christopher R TravisUNC Macromolecular Interactions Facility, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Julia VorobiovDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Shailesh ChoudharyDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Christopher L KepleyLiberty University College of Osteopathic Medicine, Lynchburg, Va.
Scott P ComminsDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Scott A SmithDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tenn; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tenn; Division of Asthma, Allergy, and Clinical Immunology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Va.
Onyinye I IwealaDivision of Rheumatology, Allergy, and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Allergy Mast Cell Disorders Program, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Division of Allergy and Immunology, Department of Pediatrics, Food Allergy Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address: onyinye.iweala@med.unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
UNC PREP in the Biomedical Sciences - Administrative SupplementR25GM089569 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBINSON, DONITA L, RODRIGUEZ-ROMAGUERA, JOSE · 2010 to 2024
$5.6M
Understanding alpha-gal red meat allergyR01AI135049 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Scott Palmer Commins · 2018 to 2026
$5.1M
Comprehensive antigenic mapping of the human anti-peanut IgE antibody responseR01AI155668 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SMITH, SCOTT ALAN · 2021 to 2025
$4.1M
Antigenic landscape of the human helminth IgE antibody responseR01AI130459 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SMITH, SCOTT ALAN · 2017 to 2021
$1.8M
Molecular details of the IgE antibody response to galactose-alpha-1,3-galactose in alpha-gal syndromeR01AI189950 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Scott Alan Smith · 2025 to 2026
$1.4M
A role for glycolipids and unconventional T cell subsets in alpha-gal allergyK08AI141691 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI IWEALA, ONYINYE I · 2020 to 2024
$998k
Studies examining quantitative in vivo imaging of breast cancer-targeted,therapeutic human mast cellsR15CA246430 · NCI · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI KEPLEY, CHRIS L · 2020 to 2020
$454k
CAR mast cell for solid tumorR21CA286364 · NCI · YALE UNIVERSITY · PI SU, XIAOLEI · 2024 to 2025
$438k
Generation and characterization of full-length naturally occurring allergen-specific human IgE mAbsR21AI123307 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SMITH, SCOTT ALAN · 2017 to 2018
$408k
NCEZID CDC HHS U01 CK000662NCI NIH HHS P30 CA016086NCI NIH HHS R15 CA246430NCI NIH HHS R21 CA286364NIAID NIH HHS K08 AI141691NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI130459NIAID NIH HHS R01 AI135049NIAID NIH HHS R01 AI155668NIAID NIH HHS R01 AI189950NIAID NIH HHS R21 AI123307NIGMS NIH HHS R25 GM089569
6 · The paper itself

Abstract

backgroundIn alpha-gal syndrome (AGS), IgE antibodies form against the glycan galactose-α-1,3-galactose (alpha-gal) in mammal products rather than food proteins. Alpha-gal glycolipids and glycoproteins activate human basophils sensitized with AGS plasma in an IgE-dependent fashion. However, it is unknown whether alpha-gal specific IgE (sIgE), independent of other blood proteins, is sufficient for mediating basophil and mast cell activation.

objectiveWe sought to determine whether alpha-gal antigens could activate passively sensitized rat basophilic leukemia (RBL) SX-38 cells, which express human IgE receptors and are commonly used to model allergen/IgE-mediated mast cell activation in food protein allergy.

methodsUsing the clustered regularly interspaced short palindromic repeats technology, we created a novel, alpha-gal-deficient RBL cell line, alpha-gal knockout RBL SX-38, passively sensitizing cells with sera from AGS donors or with novel alpha-gal sIgE clones, and then stimulated with alpha-gal glycoproteins. To assess effector cell activation, we measured cell surface expression of activation marker CD63 by flow cytometry and mediator release through β-hexosaminidase release assays.

resultsAfter alpha-gal antigen stimulation, the percentage of CD63

conclusionsCertain alpha-gal-specific human IgE clones may partially activate allergic effector cells independent of antigen, potentially lowering thresholds for subsequent alpha-gal-induced or antigen-independent allergic effector cell degranulation. This may affect duration and severity of allergic symptoms in patients with AGS.

Indexed as

BasophilsFood HypersensitivityImmunoglobulin EMast CellsAnimalsCell Line, TumorDisaccharidesHumansRatsReceptors, IgEDisaccharidesgalactosyl-(1-3)galactoseImmunoglobulin EReceptors, IgEAlpha-galalpha-gal syndromebasophilgalactose-α-1,3-galactosehuman IgEmast cellRBL SX-38

Identifiers

PMID41534718
PMCPMC13052131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.